101 related articles for article (PubMed ID: 11304897)
1. Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers.
Chevalier P; Rey J; Pasquier O; Rouzier-Panis R; Harding N; Montay G
J Clin Pharmacol; 2001 Apr; 41(4):404-14. PubMed ID: 11304897
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of quinupristin/dalfopristin.
Bearden DT
Clin Pharmacokinet; 2004; 43(4):239-52. PubMed ID: 15005638
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency.
Chevalier P; Rey J; Pasquier O; Leclerc V; Baguet JC; Meyrier A; Harding N; Montay G
Clin Pharmacokinet; 2000 Jul; 39(1):77-84. PubMed ID: 10926351
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients.
Johnson CA; Taylor CA; Zimmerman SW; Bridson WE; Chevalier P; Pasquier O; Baybutt RI
Antimicrob Agents Chemother; 1999 Jan; 43(1):152-6. PubMed ID: 9869581
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients.
Loeffler AM; Drew RH; Perfect JR; Grethe NI; Stephens JW; Gray SL; Talbot GH
Pediatr Infect Dis J; 2002 Oct; 21(10):950-6. PubMed ID: 12394819
[TBL] [Abstract][Full Text] [Related]
7. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
8. Treatment of life-threatening multiresistant staphylococcal and enterococcal infections in patients with end-stage renal failure with quinupristin/dalfopristin: preliminary report.
Schwenger V; Mündlein E; Dagrosa EE; Fahr AM; Zeier M; Mikus G; Andrassy K
Infection; 2002 Oct; 30(5):257-61. PubMed ID: 12382082
[TBL] [Abstract][Full Text] [Related]
9. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin.
Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM
J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.
Bergeron M; Montay G
J Antimicrob Chemother; 1997 May; 39 Suppl A():129-38. PubMed ID: 9511077
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
Ling TK; Fung KS; Cheng AF
Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
[TBL] [Abstract][Full Text] [Related]
13. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.
Moellering RC; Linden PK; Reinhardt J; Blumberg EA; Bompart F; Talbot GH
J Antimicrob Chemother; 1999 Aug; 44(2):251-61. PubMed ID: 10473233
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of quinupristin/dalfopristin: administration guidelines.
Rubinstein E; Prokocimer P; Talbot GH
J Antimicrob Chemother; 1999 Sep; 44 Suppl A():37-46. PubMed ID: 10511396
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
